GSK invests in Montrose

First Minister opens £54 million building.

GSK’s £54 million new state-of-the-art production building in Montrose has been opened by First Minister Nicola Sturgeon.

Active pharmaceutical ingredients (APIs) for use in GSK’s Ellipta respiratory inhalers will be produced in the building and it is the second multi-million investment on the Montrose site over the last two years.

The First Minister said:

“This new facility is testament to GSK’s commitment to Montrose and reinforces the region’s position alongside Singapore as the two sites producing APIs for all of GSK’s Ellipta respiratory inhaler portfolio.

“Scotland has a thriving life sciences community making a significant contribution to the improvement of the quality of care and health for both the people of Scotland and globally. This immensely innovative sector provides huge economic potential and, with a highly skilled workforce, makes us well placed to take advantage of the economic opportunities from innovation and technological change.”

GSK CEO Emma Walmsley said:

“The state-of-the-art facility we are opening today represents a £54 million investment in GSK Montrose and is testament to the highly-skilled workforce at the site. It also highlights the important part Montrose will play in our future growth, based around our latest medicines for respiratory, HIV and vaccines.

“GSK has a substantial manufacturing presence in Scotland and we’re delighted to welcome the First Minister back to Montrose to mark the next phase of our investment in Angus, and in Scotland’s growing life sciences industry.”

Facilities such as this allows for opportunities to grow in the Scottish life sciences industry, find out more about how your organisation could grow in Scotland here.